Methodology: IHC

Test Description

The biomarker telomerase has been shown to be upregulated in human epithelial cancers, and in bladder cancers. A key component of telomerase is a protein called human telomerase reverse transcriptase (hTERT), which can be recognised in cytological specimens by Anti-hTERT Antibody (SCD-A7) using immunocytochemistry (ICC). Specifically, the presence of hTERT in urothelial cells shed from the bladder wall into urine, can be detected in this way. A positive test for hTERT in urothelial cells indicates an altered process of some kind, and since 90% of bladder cancers upregulate telomerase, it indicates an increased chance that cancer is present.

Specimen Requirements

40 cc freshly collected urine mixed with an equal volume of PreservCyt Solution. Please indicate source urine: voided, catherized or bladder washing or one (1) unstained cytology slide prepared by cellular enhancement technique.

Storage and Transport

Store PreservCyt® Solution or NuCyte Solution with urine specimen between 4°C and 30°C. Process sample within 48 hours.

Specimen Rejection Criteria

Click here to reference the specimen rejection criteria.

Turn Around Time (TAT): 2-3 Days

CPT Codes*: 88341, 88342, 88360

*The CPT codes provided with our Test Descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.